ESR1 and breast cancer: Hormone therapy still takes up a big share of the FDA-approved drugs for breast cancer therapy, and it is not surprising since the majority of the diagnosed breast cancers are estrogen receptor (ER) positive (~80%) or ER and progesterone receptor (PR) positive (~65%) [30,31].